Skip to main content

Table 3 Rescue medication use and percentage of COPD 'days of poor control' over 12 weeks of treatment (ITT population)

From: Efficacy and safety of indacaterol 150 μg once-daily in COPD: a double-blind, randomised, 12-week study

  Treatment Treatment difference
  LSM ± SEM LSM ± SEM
Change from baseline in the mean daily number of puffs of rescue medication
Indacaterol 150 μg o.d. -1.38 ± 0.118  
   -0.97 ± 0.168*
Placebo -0.41 ± 0.122  
Change from baseline in the mean day time number of puffs of rescue medication
Indacaterol 150 μg o.d. -0.92 ± 0.076  
   -0.65 ± 0.109*
Placebo -0.27 ± 0.079  
Change from baseline in the mean night time number of puffs of rescue medication
Indacaterol 150 μg o.d. -0.47 ± 0.052  
   -0.34 ± 0.075*
Placebo -0.13 ± 0.054  
Percentage of days with no rescue use
Indacaterol 150 μg o.d. 54.63 ± 1.942  
   13.35 ± 2.791*
Placebo 41.28 ± 2.004  
Percentage of COPD 'days of poor control'
Indacaterol 150 μg o.d. 31.19 ± 1.500  
   -9.05 ± 2.175*
Placebo 40.24 ± 1.554  
  1. COPD = chronic obstructive pulmonary disease; ITT = intent-to-treat;
  2. LSM = least squares mean; SEM = standard error of the mean
  3. * p < 0.001